Comparison of the Efficacy and Safety of Docetaxel-Trastuzumab-Pertuzumab (DTP) with Standard 4-Doxorubicin and Cyclophosphamide (AC)-Taxan-Trastuzumab-Pertuzumab in Neoadjuvant Treatment of Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER-2) Positive Breast Cancer: a Turk Oncology Group (TOG) study.
Research Square (Research Square)